40.40 - 41.05
29.80 - 47.18
2.12M / 3.68M (Avg.)
18.02 | 2.27
View analysts' price targets and recommendations, and compare them with competitors.
$52.00
Lower upside than AR's upside of 54.83%.
Buy
Equal to AR's analyst recommendation of Buy.
Analyze analyst forecasts for the company and compare them with competitors.
9.39B
The estimated revenue has increased from the previous period.
1.88B
The estimated EBITDA has increased from the previous period.
4.50
The estimated EPS has decreased from the previous period.
1.21B
The estimated net income has decreased from the previous period.
-28.33M
The estimated EBIT has decreased from the previous period.
1.63B
The estimated SG&A expenses have increased from the previous period.
Analyze DCF forecasts for the company and compare them with competitors.
14.24B
Revenue has increased from the previous period.
15.56%
Revenue growth rate is unchanged from the previous period.
2.85B
EBITDA has increased from the previous period.
20.00%
EBITDA margin is unchanged from the previous period.
-42.96M
EBIT has decreased from the previous period.
-0.30%
EBIT margin is unchanged from the previous period.
2.89B
Depreciation has increased from the previous period.
151.18M
Total cash has increased from the previous period.
1.06%
Cash percentage is unchanged from the previous period.
2.03B
Receivables have increased from the previous period.
14.23%
Receivables percentage is unchanged from the previous period.
16.68M
Inventories have increased from the previous period.
0.12%
Inventory percentage is unchanged from the previous period.
654.42M
Accounts payable has increased from the previous period.
4.60%
Payables percentage is unchanged from the previous period.
-3.57B
Capital expenditure has increased from the previous period.
-25.11%
CapEx percentage is unchanged from the previous period.
12.06%
WACC is unchanged from the previous period.
16.87%
Cost of equity is unchanged from the previous period.
5.31%
Cost of debt is unchanged from the previous period.
2.64
Beta is unchanged from the previous period.
263.90M
Diluted shares outstanding is unchanged from the previous period.
6.68B
Total debt is unchanged from the previous period.
10.03B
Total equity is unchanged from the previous period.
16.71B
Total capital is unchanged from the previous period.
39.98%
Debt weighting is unchanged from the previous period.
60.02%
Equity weighting is unchanged from the previous period.
-39.29M
EBIAT has decreased from the previous period.
-910.92M
UFCF has increased from the previous period.
0.50%
Long-term growth rate is unchanged from the previous period.
-12.22B
Terminal value is unchanged from the previous period.
-10.90B
Enterprise value is unchanged from the previous period.
6.68B
Net debt is unchanged from the previous period.
-17.58B
Equity value is unchanged from the previous period.
-66.63
Equity value per share is unchanged from the previous period.
